To test this hypothesis, we evaluated the association of polymorphisms in PD-1, PD-L1, and CTLA-4 genes with the chemotherapy response and survival of NSCLC patients undergoing 1st line paclitaxel-cisplatin chemotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.